Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxytryptamine (5-HT(1B/1D)) receptors

British Journal of Pharmacology

Volumn 122, Issue 5, 1997, Pages 918-922

  Goadsby, Peter J ^a   Knight, Yolande ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Blood brain barrier; Headache; Migraine; Sumatriptan; Trigeminovascular

Indexed keywords

N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NARATRIPTAN; SEROTONIN 1 AGONIST; SEROTONIN 1 ANTAGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CAT; ELECTROSTIMULATION; INTRAVENOUS DRUG ADMINISTRATION; LAMINECTOMY; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD; SPINAL CORD DORSAL HORN; SPINAL CORD STIMULATION; SUPERIOR SAGITTAL SINUS; TRIGEMINAL NERVE;

ANIMALS; CATS; CRANIOTOMY; ELECTRIC STIMULATION; EVOKED POTENTIALS, SOMATOSENSORY; INDOLES; INJECTIONS, INTRAVENOUS; NEURONS; OXADIAZOLES; PIPERAZINES; PIPERIDINES; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; TRIGEMINAL NUCLEUS, SPINAL; TRYPTAMINES;

EID: 0030771082     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701456     Document Type: Article

References (52)

1. BOUCHELET, I., COHEN, Z., CASE, B. & HAMEL, E. (1996). Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Molec. Pharmacol., 50, 219-223.
2. 1D antagonists. J. Med. Chem., 37, 2253-2257.
3. CUMBERBATCH, M.J., HILL, R.G. & HARGREAVES, R.J. (1997). Rizatriptan has central antinociceptive effects against durally evoked potentials. Eur. J. Pharmacol., 328, 37-40.
4. FANCIULLACCI, M., ALESSANDRI, M., FIGINI, M., GEPPETTI, P. & MICHELACCI, S. (1995). Increases in plasma calcitonin gene-related peptide from extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain, 60, 119-123.
5. FEINDEL, W., PENFIELD, W. & MCNAUGHTON, F. (1960). The tentorial nerves and localisation of intracranial pain in man. Neurology, 10, 555-563.
6. FERRARI, M.D. (1991). Treatment of migraine attacks with sumatriptan. New Eng. J. Med., 325, 316-321.
7. GALLAI, V., SARCHIELLl, P., FLORIDI, A., FRANCESCHINI, M., CODINI, M., TREQUATTRINI, A. & PALUMBO, R. (1995). Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia, 15, 384-390.
8. GOADSBY, P.J. (1994). Cluster headache and the clinical profile of sumatriptan. Eur. Neurol., 34(Suppl), 35-39.
9. GOADSBY, P.J. (1997). Bench to bedside: what have we learnt recently about headache? Curr. Op. Neurol., 10, 215-220.
10. 1D receptor agonist 311C90. Headache, 34, 299-300.
11. GOADSBY, P.J., EDVINSSON, L. & EKMAN, R. (1990). Vasoactive peptides release in the extracerebral circulation of humans during migraine headache. Ann. Neurol., 28, 183-187.
12. 3H]-dihydroergotamine binding sites in the cat central nervous system: relevance to migraine. Ann. Neurol., 29, 91-94.
13. GOADSBY, P.J. & HOSKIN, K.L. (1996). Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)-1-D receptor agonist zolmitriptan (311C90): are brain stem sites a therapeutic target in migraine? Pain, 67, 355-359.
14. GOADSBY, P.J. & HOSKIN, K.L. (1997). The distribution of trigeminovascular afferents in the non-human primate brain rnacaca nemestrina: a c-fos immunocytochemical study. J. Anat., 190, 367-375.
15. GOADSBY, P.J. & KNIGHT, Y.E. (1997). Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia, 17, 153-158.
16. GOADSBY, P.J. & ZAGAMI, A.S. (1991). Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain, 114, 1001-1011.
17. 1b binding sites in rat brain membranes: evidence for guanine nucleotide regulation of agonist affinity states. J. Pharmacol. Exp. Ther., 243, 989-1001.
18. 1Dβ receptor subtype in human bovine and cerebral arteries. Molec. Pharmacol., 44, 242-246.
19. HARTIG, P.R., HOYER, D., HUMPHREY, P.P.A. & MARTIN, G.R. (1996). Alignment of receptor nomenclature with the human genome: classification of 5HT-1B and 5-HT1D receptor subtypes. Trends Pharmacol. Sci., 17, 103-105.
20. HOSKIN, K.L., KAUBE, H. & GOADSBY, P.J. (1996a). Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: a c-Fos and electrophysiology study. Brain, 119, 249-256.
21. HOSKIN, K.L., KAUBE, H. & GOADSBY, P.J. (1996b). Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain, 119, 1419-1428.
22. HOYER, D., CLARKE, D.E., FOZARD, J.R., HARTIG, P.R., MARTIN, G.R., MYELCHARANE, E.J., SAXENA, P.R. & HUMPHREY, P.P.A. (1994). International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev., 46, 157-203.
23. HU, J.W., DOSTROVOSKY, J.O. & SESSLE, B.J. (1981). Functional properties of neurons in the cat trigeminal subnucleus caudalis (medullary dorsal horn). I. Responses to oro-facial noxious and nonnoxious stimuli and projections to thalamus and subnucleus oralis. J. Neurophysiol., 45, 173-191.
24. HUMPHREY, P.P.A., FENIUK, W., MARRIOTT, A.S., TANNER, R.J.N., JACKSON, M.R. & TUCKER, M.L. (1991). Preclinical studies on the anti-migraine drug, sumatriptan. Eur. Neurol., 31, 282-290.
25. HUMPHREY, P.P.A. & GOADSBY, P.J. (1994). Controversies in headache. The mode of action of sumatriptan is vascular? a debate. Cephalalgia, 14, 401-410.
26. KAUBE, H., HOSKIN, K.L. & GOADSBY, P.J. (1992). Activation of the trigeminovascular system by mechanical distension of the superior sagittal sinus in the cat. Cephalalgia, 12, 133-136.
27. KAUBE, H., HOSKIN, K.L & GOADSBY, P.J. (1993a). Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. Br. J. Pharmacol., 109, 788-792.
28. KAUBE, H., KEAY, K., HOSKIN, K.L., BANDLER, R. & GOADSBY, P.J. (1993b). Expression of c-fos-like immunoreactivity in the trigeminal nucleus caudalis and high cervical cord following stimulation of the sagittal sinus in the cat. Brain Res., 629, 95-102.
29. KELLER, J.T., SAUNDERS, M.C., BEDUK, A. & JOLLIS, J.G. (1985). Innervation of the posterior fossa dura of the cat. Brain Res. Bull., 14, 97-102.
30. KIMBALL, R.W., FRIEDMAN, A.P. & VALLEJO, E. (1960). Effect of serotonin in migraine patients. Neurology (Minneap.), 10, 107-111.
31. 1B/1D receptor. Cephalalgia, 17, 403.
32. LANCE, J.W., ANTHONY, M. & HINTERBERGER, H. (1967). The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome. Headache, 7, 93-102.
33. MCNAUGHTON, F.L. & FEINDEL, W.H. (1977). Innervation of intracranial structures: a reappraisal. In Physiological Aspects of Clinical Neurology, ed. Rose, F.C. pp. 279-293. Oxford: Blackwell Scientific Publications.
34. 3H]sumatriptan binding in cat brain stem and spinal cord. Eur. J. Pharmacol., 280, 175-178.
35. O'SHAUGHNESSY, C.T., CONNOR, H.E. & FENIUK, W. (1993). Extracellular recordings of membrane potential from guinea-pig isolated trigeminal ganglion: lack of effect of sumatriptan. Cephalalgia, 13, 175-179.
36. 3H]sumatriptan binding sites in human brain: regional-dependent labelling of 5HT1D and 5HT1F receptors. Eur. J. Pharmacol., 295, 271-274.
37. PENFIELD, W. (1934). A contribution to the mechanism of intracranial pain. Proc. Assoc. Res. Nervous and Mental Dis., 15, 399-415.
38. PENFIELD, W. & MCNAUGHTON, F.L. (1940). Dural headache and the innervation of the dura mater. Arch. Neurol. Psychiatry, 44, 43-75.
39. 1F receptor agonist, in the neurogenic dural inflammation model of migraine pain. Proc. Soc. Neurosci. (U.S.A.), 22, 1331.
40. RANCE, D., CLEAR, N., DALLMAN, L., LLEWELLYN, E., NUTTALL, J. & VERRIER, H. (1997). Physicochemical comparison of eletriptan and other 5-HT1D-like agonists as a predictor or oral absorption potential. Headache, 37, 328.
41. RAY, B.S. & WOLFF, H.G. (1940). Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Arch. Surgery, 41, 813-856.
42. REBKCK, G.W., MAYNARD, K.I., HYMAN, B.T. & MOSKOWITZ, M.A. (1994). Selective 5HT1D alpha serotonin receptor gene expression in trigeminal ganglion: implications for antimigraine drug development. Proc. Natn. Acad. Sci. U.S.A., 91, 3666-2669.
43. SCHOENEN, J., -CECCHINI, A.P. & AFRA, J. (1996). Evidence in man for a central effect of a 5-HT-1D-agonist, 311C90, from a study of the intensity dependence of the cortical evoked potential. Eur. J. Neurol., 3 (Suppl 5), 88.
44. SHEPHEARD, S.L., WILLIAMSON, D.J., WILLIAMS, J., HILL, R.G. & HARGREAVES, R.J. (1995). Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in the dura mater and c-fos mRNA expression in the trigeminal nucleus caudalis of rats. Neuropharmacology, 34, 255-261.
45. SIEGEL, S. (1956). Non-Parametric Statistics for the Behavioural Sciences. Kogakusha, Tokyo: McGraw-Hill.
46. 1A autoreceptors modulate 5-HT release in the guinea pig dorsal raphe nucleus. Neuropharmacology, 33, 393-402.
47. TFELT-HANSEN, P., HENRY, P., MULDER, L.J., SCHELDEWAERT, R.G., SCHOENEN, J. & CHAZOT, G. (1995). The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared to oral sumatriptan for migraine. Lancet, 346, 923-926.
48. 3H]sumatriptan labels both 5-HT1D and 5HT-1F receptor bindings sites in the guinea pig brain: an autoradiographic study. Naunyn-Schmiedeberg's Arch. Pharmacol., 352, 263-275.
49. WINNER, P., RICALDE, O., FORCE, B.L., SAPER, J. & MARGUL, B. (1996). A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch. Neurol., 53, 180-184.
50. WOLFF, H.G. (1963). Headache and Other Head Pain. New York: Oxford University Press.
51. 1D antagonist properties. Cephalalgia, 17, 404.
52. ZAGAMI, A.S., GOADSBY, P.J. & EDVINSSON, L. (1990). Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides, 16, 69-75.